Validated HPLC Methods

Similar documents
Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Appendix II- Bioanalytical Method Development and Validation

4.A.1 Discussion. Assay method development and Validation of Ziprasidone Hydrochloride

Chapter 4: Verification of compendial methods

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

LC and LC/MS Column Selection Flow Chart

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were

High Performance Liquid Chromatography. Table 1: Allowed HPLC Adjustment of USP <621> and EP <2.2.46>

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

International Journal of Current Trends in Pharmaceutical Research. International Journal of Current Trends in Pharmaceutical Research

The Secrets of Rapid HPLC Method Development. Choosing Columns for Rapid Method Development and Short Analysis Times

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Agilent 1200 Infinity Series HDR DAD Impurity Analyzer System for the Quantification of Trace Level of Genotoxic Impurity

Method Development and Validation for the Estimation of Darunavir in Rat Plasma by RP-HPLC

Streamlining the Analysis of Oral Contraceptives Using the ACQUITY UPLC H-Class System

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

Quantification of growth promoters olaquindox and carbadox in animal feedstuff with the Agilent 1260 Infinity Binary LC system with UV detection

Eliminating Unwanted Variability in LC Methods: More Uptime, More Sample Throughput

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

Journal of Chemical and Pharmaceutical Research

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

A Quality by Design (QbD) Based Method Development for the Determination of Impurities in a Peroxide Degraded Sample of Ziprasidone

Barry E. Boyes, Ph.D. Consumables and Accessories Business Unit May 10, 2000

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Atovaquone

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS.

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

serve the goal of analytical lmethod Its data reveals the quality, reliability and consistency of

Shodex TM ODP2 HP series columns

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

Application Note. Pharmaceutical QA/QC. Author. Abstract. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Dilution(*) Chromatography

KEYWORDS: Acetaminophen, Doxylamine succinate, Dextromethorphan hydrobromide.

William E. Barber, Ph.D. Applications Chemist October

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

Welcome to our E-Seminar: Choosing HPLC Columns for Faster Analysis Smaller and Faster

HPLC Separation Robustness and Ruggedness Assessing the Effects of Experimental Variables During Method Development

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF GABAPENTIN IN PURE AND PHARMACEUTICAL FORMULATIONS

Agilent s New Weak Anion Exchange (WAX) Solid Phase Extraction Cartridges: SampliQ WAX

Analytical Performance & Method. Validation

SIMPLE AND SENSITIVE VALIDATED REVERSE PHASE HPLC-UV METHOD FOR THE DETERMINATION OF LYMECYCLINE IN PHARMACEUTICAL DOSAGE FORMS

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

Radhakrishnan K. et al. / International Journal of Pharmacy & Therapeutics, 3(1), 2012, e- ISSN Print ISSN

International Journal of Pharma and Bio Sciences V1(1)2010. HPLC method for analysis of Lercanidipine Hydrochloride in Tablets

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Estimation of zaleplon by a new RP-HPLC method

INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND LIFE SCIENCES

Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

Work plan & Methodology: HPLC Method Development

AND VALIDATION FOR SIMULTENEOUS ESTIMATION OF AMBROXOL HYDROCHLORIDE AND DOXOFYLLINE IN PHARMACEUTICAL DOSAGES FORMS AND BULK DRUGS BY RP-HPLC METHOD

Sravani and Haritha Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:

In the present analytical project, an attempt has been made to develop a simple, economical and reliable liquid

Method Development and Validation of Tramadol Hydrochloride by RP-HPLC Method

LC Determination of Deferasirox in Pharmaceutical Formulation

DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS

Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3

Validation of ACQUITY UPLC Methods

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

Application Note. Author. Abstract. Pharmaceutical QA/QC. Vinayak A.K Agilent Technologies Bangalore, India

Fast methods for the determination of ibuprofen in drug products

Rapid and simultaneous determination of paracetamol, ibuprofen and related impurity of ibuprofen by UPLC/DAD

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

Value of Eclipse Plus C18 and ph Selectivity to Analyze Amine-Containing Drugs

Application Note Pharmaceutical QA/QC. Agilent Application Solution. Authors. Abstract. Syed Salman Lateef Agilent Technologies, Inc.

International Journal of Pharmaceutical Research & Analysis

Low-level Determination of 4-Hydrazino Benzoic Acid in Drug Substance by High Performance Liquid Chromatography/Mass Spectrometry

Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

BRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF IVABRADINE HCL IN BULK AND FORMULATION

IDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)

Choosing Columns and Conditions for the Best Peak Shape

The Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

Impact factor: 3.958/ICV: 4.10 ISSN:

Advantages of polymerbased. an alternative for ODS

UPLC Method Development and Validation

Saudi Journal of Medical and Pharmaceutical Sciences

Additionally, minor editorial changes have been made to update the monograph to current USP style.

Liquid Chromatography and Spectroscopic Method for Estimation of Sulphadoxine in Marketed Formulation

Volume 6, Issue 2, January February 2011; Article-015

Intercontinental journal of pharmaceutical Investigations and Research

International Journal of Pharma and Bio Sciences

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR QUANTIFICATION OF CIPROFLOXACIN HCL, ITS RELEATED SUBSTANCE AND TINIDAZOLE IN TABLET DOSAGE FORM

Development and validation a RP-HPLC method: Application for the quantitative determination of quetiapine fumarate from marketed bulk tablets

Transcription:

Validated HPLC Methods To Tweak or Not to Tweak Slide 4

Adjustments of operating conditions to meet system suitability requirements may be necessary. USP 23 p1776 Slide 5 001816S1.PPT

What is the line between adjusting conditions and actually modifying an official or regulatory method? This is critical to know because modifying a method requires validation and ruggedness testing. Slide 6 001817S1.PPT

Let s examine some proposed guidelines for this area. System Suitability Tests in Regulatory Liquid and Gas Chromatographic Methods: Adjustments Versus Modifications William B. Furman, John G. Dorsey, and Lloyd R. Snyder Pharmaceutical Technology, June 1998 p. 58-64 Slide 7 001818S1.PPT

HPLC Method Parameters That Can Be Varied Mobile Phase The ph of the mobile phase: +/- 0.2 ph units Concentration of the buffer salts: +/- 10% (buffer ph must remain same +/- 0.2 ph units) Ratio of the solvents in the mobile phase: +/- 30% relative or +/- 2% absolute, whichever is larger, but no change can exceed 10% (based on mobile phase component of 50% or less) Slide 8 001819S1.PPT

HPLC Method Parameters That Can Be Varied Column Column length: +/- 70% (250 mm columns may be substituted over the range 75 425 mm) Column inner diameter: +/- 25% (if method calls for 3.9 mm id, 3.0, 4.0, or 4.6 mm can be substituted) Particle size: may be reduced up to 50% (3 or 3.5 µm particles can be used instead of 5 µm) Column temperature: +/- 20 C Slide 9 001820S1.PPT

HPLC Method Parameters That Can Be Varied System Flow Rate: +/- 50% Injection Volume: - Increase up to 2x maintain peak shape, resolution, retention time, etc. - Decrease as much as will maintain acceptable precision and sensitivity Slide 10 001821S1.PPT

Let s look at a problem method and determine if it can be adjusted or must be modified. Slide 11 001822S1.PPT

USP Diphenhydramine Hydrochloride Method Mobile Phase: Column: Flow Rate: Detection: System Suitability: Specifications: 50% Acetonitrile: 50% Water: 0.5% Triethylamine Prepare solution and adjust ph to 6.5 with glacial acetic acid 4.6 x 250 mm, L10 (CN) 1mL/min UV 254 nm Benzophenone and Diphenhydramine Solution Rs > 2.0, Tf < 2.0 for diphenhydramine Slide 12 001823S1.PPT

Method Problems October 28 Apparent ph 6.5 November 1 Apparent ph 6.2 November 6 Apparent ph 6.2 D B D B Cyano Cyano Cyano D B D D B SB-CN SB-CN SB-CN B D B 0 2 4 6 8 10 Time (min) 0 2 4 6 8 10 Time (min) 0 2 4 6 8 10 Time (min) The ph drifts and retention changes because of unreliable ph adjustment on mobile phase with organic present. The traditional CN column shows more changes than the SB-CN column. Slide 13 001824S1.PPT

Method Adjustment Adjust ph on aqueous component alone. This is done by measuring the amount of acid it requires to get to the apparent ph, then adding this amount to the aqueous component (with TEA). This becomes the new ph of the mobile phase. This procedure works best if the mobile phase is actually buffered. Slide 14 001825S1.PPT

Recommendations Use a proper buffer and make the ph adjustment to the aqueous portion alone, but keep the mobile phase as similar as possible to maintain expected behavior. Select a Rapid Resolution L10 column to minimize analysis time and maintain resolution. Use an SB-CN (L10) to improve reproducibility. Slide 15 001826S1.PPT

Modified Diphenhydramine Hydrochloride Method Parameters Column: 4.6 x 75 mm, 3.5 mm, StableBond SB-CN (L10) 1 Mobile Phase: 55% 25 mm ammonium acetate ph 4.5/ 0.5% TEA: 45% Acetonitrile 2 Flow Rate: 1mL/min Detection: UV 265 nm 2 Temperature: System Suitability: Specifications: RT Benzophenone and Diphenhydramine Solution Rs > 2.0, Tf < 2.5 for diphenhydramine 1 method adjustment 2 method modification Slide 16 001827S1.PPT

Modified Diphenhydramine Hydrochloride Method Example Column: StableBond SB-CN Mobile Phase: 55% 25 mm CH 3 COONH 4 /0.5% TEA : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 2. Benzophenone Injection Volume: 10 µl Detection: UV 265 nm 4.6 x 250 mm, 5 µm R s = 7.5 T f = 1.5 1 1 4.6 x 75 mm, 3.5 µm R s = 5.9 T f = 1.4 2 2 0 5 10 Time (min) 0 1 2 3 4 5 Time (min) Slide 17 001828S1.PPT

Break Number 1 For Questions and Answers Press *1 on Your Phone to Ask a Question Slide 18

Method Validation Requirements Robustness Linearity Accuracy Precision Limit of Detection Limit of Quantitation Specificity/Selectivity Range Ruggedness Slide 19 001829S1.PPT

USP Data Requirements for Method Validation Impurities Product Parameter Bulk Drug Degradates Performance Precision Yes Yes Yes Accuracy Yes Yes Maybe Limit of Detection No No Maybe Limit of Quantitation No Yes Maybe Specificity/Selectivity Yes Yes Maybe Range Yes Yes Maybe Linearity Yes Yes Maybe Ruggedness Yes Yes Yes Slide 20 001830S1.PPT

Robustness Testing Vary Key Method Parameters - meet or exceed method adjustment recommendations Use System Suitability Mixture - diphenhydramine/benzophenone and focus on behavior of diphenhydramine 1. ph 2. Temperature 3. % Organic 4. Buffer Concentration 5. Column Lot Slide 21 001831S1.PPT

ph Variation Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% 25 mm CH 3 COONH 4 /0.5% TEA : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 0.5 mg/ml 2. Benzophenone.005 mg/ml Injection Volume: 10 ml Tested ph at 4.0, 4.5, and 5.0. Monitor for substantial changes in retention, resolution, and peak shape ph Time R s T f A 4.0 1.78 6.2 1.7 B 4.5 1.94 5.5 1.7 C 5.0 2.14 4.0 1.8 1 1 A B C 1 2 2 2 0 1 2 3 4 5 Time (min) 0 1 2 3 4 5 Time (min) 0 1 2 3 4 5 Time (min) Slide 22 001832S1.PPT

Buffer Concentration Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% CH 3 COONH 4 (ph 4.5)/0.5% TEA : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 0.5 mg/ml 2. Benzophenone.005 mg/ml Injection Volume: 10 ml 1 Conc. Time T f 2 A 20 mm 1.98 1.8 B 25 mm 1.96 1.8 C 30 mm 1.99 1.8 C B A Tested two additional buffer strengths, 20 mm and 30 mm Monitor for changes in retention and peak shape 0 1 2 3 4 5 Time (min) Slide 23 001833S1.PPT

Temperature Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% CH 3 COONH 4 (ph 4.5)/0.5% TEA : 45% ACN Flow Rate: 1.0 ml/min Temperature: see below Sample: 1. Diphenhydramine 0.5 mg/ml 2. Benzophenone.005 mg/ml Injection Volume: 10 µl 1 2 C α T f A RT 1.6 1.8 B 30 1.6 1.7 C 35 1.6 1.7 C B A Tested 3 temperatures Room Temperature, 30 C and 35 C Monitor for changes in selectivity (α) and peak shape of diphenhydramine 0 1 2 3 4 5 Time (min) Slide 24 001834S1.PPT

% Organic Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: CH 3 COONH 4 (ph 4.5)/0.5% TEA : ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 0.5 mg/ml 2. Benzophenone.005 mg/ml Injection Volume: 10 ml 1 % ACN R t k R s 2 A 40 2.27 2.0 7.5 B 43 2.07 1.8 6.4 C 45 1.96 1.6 5.0 D 50 1.75 1.3 2.8 Time (min) D C B A 0 1 2 3 4 5 Expect retention, selectivity and resolution to change with change in organic. Determine which mobile phase meets needs (adequate retention, resolve matrix components) without wasting time. Slide 25 001835S1.PPT

Column Lot Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% CH 3 COONH 4 (ph 4.5)/0.5% TEA : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 0.5 mg/ml 2. Benzophenone.005 mg/ml Injection Volume: 10 ml 1 2 Compare three current lots of material for consistency of retention (k) and selectivity (α). Lot B98001 Lot B97110 Lot B97077 Three Lot Summary Mean SD RSD k (D) 1.1 0.01 1.0% k (B) 2.9 0.06 2.1% α 2.6 0.05 1.8% 0 1 2 3 Time (min) Slide 26 001836S1.PPT

Break Number 2 For Questions and Answers Press *1 on Your Phone to Ask a Question Slide 27

Method Validation Requirements Robustness Linearity Accuracy Precision Limit of Detection Limit of Quantitation Specificity/Selectivity Range Ruggedness Slide 28 001837S1.PPT

Linearity How? Regression analysis of test results vs analyte concentration. For the bulk substance type of samples we must cover a range of 80-120% of the expected concentration. 1000000 800000 Diphenhydramine Linearity R 2 = 0.9999 Area Area 600000 400000 200000 Predicted Area Linear (Area) 0 0 50 100 150 Level (%) Slide 29 001838S1.PPT

Accuracy How? Calculate % recovery of known amounts added to samples above and below expected levels. We tested the ICH* recommended 3 replicates at 3 different levels one above and two below. Level Results Accuracy 125% 99.6 +/- 0.2% 75% 100.3 +/- 0.8% 25% 99.2 +/- 0.7% * ICH - International Conference on Harmonization Slide 30 001839S1.PPT

Precision/Repeatability How? Calculate (relative) standard deviation of a sufficient number of sample aliquots. This can be from three levels three repetitions or 6 determinations at 100%. Results Level SD RSD 125% 0.16 0.2% 75% 0.76 0.8% 25% 0.67 0.7% Slide 31 001840S1.PPT

Limit of Detection* Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% 25 mm CH 3 COONH 4, ph 4.5 : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 1 How? Signal-to-noise ratio of 2:1 or 3:1 is generally accepted. Compare to blank. We used a S/N of 3:1. Result 0.2 ppm (2 ng on column) 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 Time (min) *not required for validation of this method Slide 32 001841S1.PPT

Limit of Quantitation* 1 2 How? Determine the standard deviation of blank response x10. Verify accuracy and precision with samples close to the calculated limit. Result 1.2 ppm (12 ng on column) with precision = 5.9% 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 Time (min) *not required for validation of this method Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% 25 mm CH 3 COONH 4, ph 4.5 : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine 2. Benzophenone Slide 33 001842S1.PPT

Specificity/Selectivity Column: SB-CN, 4.6 x 75 mm, 3.5 µm Mobile Phase: 55% 25 mm CH 3 COONH 4, ph 4.5 : 45% ACN Flow Rate: 1.0 ml/min Temperature: RT Sample: 1. Diphenhydramine Fresh Tablet Degraded Tablet 1 1 How? Compare test results from samples with impurities, degradation products, excipients etc. with those without. 0 1 2 3 4 5 Time (min) 0 1 2 3 4 5 Time (min) Slide 34 001843S1.PPT

Range How? Verify acceptable precision, accuracy, and linearity at the ends of the range and within the range. Our tested range went up to the 175% level. Therefore we needed to verify linearity, accuracy, and precision at this level, in addition to those done previously. Diphenhydramine Linearity Extended Range Area 1500000 1000000 R 2 = 0.9998 Area 500000 0 0 100 200 Predicted Area Linear (Area) Level (%) Level Acc. SD RSD 175% 100.6% 0.40 0.4% Slide 35 001844S1.PPT

Ruggedness/Reproducibility How? Multiple chemists in multiple labs run samples. Results should be reproducible and can be compared to method precision. Result Samples were run in 3 labs by 3 chemists on 3 different instruments. Chemist 1 Chemist 2 Chemist 3 Level Accuracy/RSD Accuracy/RSD Accuracy/RSD 125% 99.6 +/- 0.2% 100.2 +/- 0.8% 99.0 +/- 0.8% 75% 100.3 +/- 0.8% 100.5 +/- 0.0% 100.5 +/- 0.3% 125% 99.2 +/- 0.7% 100.6 +/- 0.0% 101.0 +/- 0.7% Overall 99.7 +/- 0.9% 100.4 +/- 0.4% 100.2 +/- 1.0% Method 100.0 +/- 0.9% Slide 36 001845S1.PPT

Determining System Suitability Specifications What type of variation do you see normally and how much leeway do you want? What makes accurate chromatographic results possible? Try to account for column degradation and insufficiently tested methods. Slide 37 001846S1.PPT

System Suitability Setting System Suitability Specifications: Tailing Factor < 2.5 (allows for higher sample load) Resolution > 2.0 (allows for method variation and column aging) RSD of replicate injections < 2.0% (checks system performance) Slide 38 001847S1.PPT

Conclusions New suggested guidelines may make it easier to determine what is a method adjustment to meet system suitability requirements. When needed method modifications exceed adjustments then method validation is required. Method validation requires experimentation to verify that a method will meet analytical needs. Slide 39 001848S1.PPT

Acknowledgments Agilent Technologies LFAD, Newport Site John Henderson Bud Permar Slide 40 001849S1.PPT

Wrap-up E-Seminar Questions Slide 41